LLY

1,015.42

-0.45%↓

JNJ

243.44

-0.97%↓

ABBV

225.92

+0.78%↑

NVS

163.49

+0.13%↑

MRK

121.71

-0.06%↓

LLY

1,015.42

-0.45%↓

JNJ

243.44

-0.97%↓

ABBV

225.92

+0.78%↑

NVS

163.49

+0.13%↑

MRK

121.71

-0.06%↓

LLY

1,015.42

-0.45%↓

JNJ

243.44

-0.97%↓

ABBV

225.92

+0.78%↑

NVS

163.49

+0.13%↑

MRK

121.71

-0.06%↓

LLY

1,015.42

-0.45%↓

JNJ

243.44

-0.97%↓

ABBV

225.92

+0.78%↑

NVS

163.49

+0.13%↑

MRK

121.71

-0.06%↓

LLY

1,015.42

-0.45%↓

JNJ

243.44

-0.97%↓

ABBV

225.92

+0.78%↑

NVS

163.49

+0.13%↑

MRK

121.71

-0.06%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.39 2.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.38

Max

1.3900000000000001

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+239.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	18M 144M
Eelmine avamishind	-0.82
Eelmine sulgemishind	1.39

Uudiste sentiment

By Acuity

50%

162 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. veebr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

19. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19. veebr 2026, 23:38 UTC

Tulu

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19. veebr 2026, 23:38 UTC

Tulu

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19. veebr 2026, 23:38 UTC

Tulu

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19. veebr 2026, 23:37 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19. veebr 2026, 23:34 UTC

Tulu

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19. veebr 2026, 23:34 UTC

Tulu

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19. veebr 2026, 23:33 UTC

Tulu

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19. veebr 2026, 23:33 UTC

Tulu

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19. veebr 2026, 22:13 UTC

Market Talk

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19. veebr 2026, 22:08 UTC

Tulu

Fairfax Financial 4Q Rev $8.11B >FFH.T

19. veebr 2026, 22:07 UTC

Tulu

Eldorado Gold 4Q EPS $1.19 >ELD.T

19. veebr 2026, 22:06 UTC

Tulu

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19. veebr 2026, 22:05 UTC

Tulu

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19. veebr 2026, 22:05 UTC

Tulu

Eldorado Gold 4Q Rev $577.2M >ELD.T

19. veebr 2026, 22:04 UTC

Tulu

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19. veebr 2026, 22:04 UTC

Tulu

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19. veebr 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

19. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19. veebr 2026, 21:43 UTC

Tulu

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19. veebr 2026, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19. veebr 2026, 21:42 UTC

Tulu

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19. veebr 2026, 21:41 UTC

Tulu

Correct: St Barbara 1H Net Loss A$249,000

19. veebr 2026, 21:40 UTC

Tulu

St Barbara 1H Net Loss A$249 Million

19. veebr 2026, 21:39 UTC

Tulu

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19. veebr 2026, 21:37 UTC

Tulu

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19. veebr 2026, 21:37 UTC

Tulu

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

239.29% tõus

12 kuu keskmine prognoos

Keskmine 4.75 USD 239.29%

Kõrge 7 USD

Madal 2.5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

162 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.